Results 161 to 170 of about 259,590 (298)

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad   +22 more
wiley   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco   +17 more
wiley   +1 more source

Soft Tissue Sarcoma Burden and Research Productivity: Global Patterns and Disparities, 1990–2021

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Soft tissue sarcoma (STS) is a rare and diverse type of cancer, with a disproportionate incidence and limited global epidemiological studies. This study aims to analyze the long‐term trends and epidemiological features of the global burden of STS from 1990 to 2021 and to reveal the global research productivity on STS.
Hongjie Pan   +8 more
wiley   +1 more source

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam   +19 more
wiley   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy